With patients more and more frequently turning to digital channels for their health information, many drugmakers are headed that direction with their marketing, too. But when looking at how to market Teva's QVAR inhalation aerosol, the Israeli company, in conjunction with Merkley + Partners, asked an important question.
On Monday, Teva CFO Eyal Desheh told listeners at the Morgan Stanley Global Healthcare Conference in New York that the Israeli drugmaker has no new plans for major job cutbacks.
Even as the FDA is questioning the widespread use of testosterone-boosting drugs for men, the Federal Trade Commission has sued AbbVie and Teva Pharmaceutical Industries for keeping a generic of one out of their reach for years. It is one of the first actions brought by the FTC since the Supreme Court last year said that so-called pay-for-delay deals are not inherently illegal.
Ring up another win for Teva in its fight to roll out a generic of AstraZeneca's Symbicort in Europe--and another loss for aging respiratory blockbusters trying to hoard their market share. The English High Court has sided with Teva in a patent case, invalidating one of AZ's IP shields on the drug.
After trying nearly everything in its power to protect lead product Copaxone from early generic competition, Teva just received some news it least wants to hear: Copycats are going after its new, long-acting version of the drug, too.
Teva Pharmaceutical Industries, whose manufacturing operation is being signifcantly pared down, is recalling one lot of its generic Parkinson's combo drug carbidopa/levodopa because it may have too much active pharmaceutical ingredient.
Teva's long-acting version of multiple sclerosis treatment Copaxone has surpassed most analysts' expectations. But as competition to the original looms, will Teva consider discontinuing off-patent Copaxone to push patients toward the protected version in a quest to maintain market share? The short answer: Yes, but not just yet.
Teva Pharmaceutical Industries, which in April had to recall a children's growth hormone, has now halted production of a parenteral nutrition product as the authorities try to determine why 9 children in Israel developed blood infections after taking it.
Rebel investor Benny Landa has already won some of his demands from Teva's leadership, including a smaller board with more pharma experience. Now, he's angling for more boardroom changes--and if Teva won't make them, he says, he will.
Controversial Teva chairman Phillip Frost may not be leaving until the end of this year, but the company already has its next chairman lined up. That's according to one of the company's activist investors. And he doesn't much like its pick.